T-follicular helper (TFH) lymphoma is a blood cancer subgroup that continues to demonstrate a generally poor prognosis, with no standard treatment established to date. Although specific genetic ...

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which ...

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response ...

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with ...

In a recent Q&A hosted by Susan Thornton, CEO of the Cutaneous Lymphoma Foundation, a patient advocacy group, Dr. Kim shared her gratitude to clinical trial participants and emphasized the urgent need ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A home-based care program improved urgent visits, symptom burden, and daily function, despite not having a significant effect on hospital admissions and ED visits.

A newly renovated multi-family home in Brookline is offering free stays to families who travel to the Boston area because a ...

The awards — both diversity supplement funding to the same cohort study on lymphoma — were terminated on March 31, but only ...